EGFR and head and neck cancer: Notably, however, head and neck cancer (HNSC) has a dearth of unique CAR targets, with only two targets currently in clinical trials, EGFR and ERBB2, suggesting that there may be a critical unmet need to identify additional cell surface targets for HNSC.